Evotec SE ADR (EVO) - Total Liabilities
Based on the latest financial reports, Evotec SE ADR (EVO) has total liabilities worth $941.17 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Evotec SE ADR - Total Liabilities Trend (2003–2025)
This chart illustrates how Evotec SE ADR's total liabilities have evolved over time, based on quarterly financial data. See EVO working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Evotec SE ADR Competitors by Total Liabilities
The table below lists competitors of Evotec SE ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suofeiya Home Collection Co Ltd
SHE:002572
|
China | CN¥5.50 Billion |
|
ABOUT YOU Holding AG
F:YOU
|
Germany | €902.70 Million |
|
Reit 1
TA:RIT1
|
Israel | ILA4.85 Billion |
|
Via Transportation, Inc.
NASDAQ:VIA
|
USA | $101.19 Million |
|
Chengdu Gas Group Co Ltd
SHG:603053
|
China | CN¥2.96 Billion |
|
Limin Chemical Co Ltd
SHE:002734
|
China | CN¥2.52 Billion |
|
Hiecise Precision Equipment Co Ltd
SHE:300809
|
China | CN¥570.43 Million |
|
Ambea AB
ST:AMBEA
|
Sweden | Skr15.81 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Evotec SE ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EVO company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evotec SE ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evotec SE ADR (2003–2025)
The table below shows the annual total liabilities of Evotec SE ADR from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $964.64 Million | +0.49% |
| 2024-12-31 | $959.98 Million | -18.59% |
| 2023-12-31 | $1.18 Billion | +10.19% |
| 2022-12-31 | $1.07 Billion | +24.79% |
| 2021-12-31 | $857.48 Million | -9.86% |
| 2020-12-31 | $951.26 Million | +12.66% |
| 2019-12-31 | $844.39 Million | +143.34% |
| 2018-12-31 | $347.00 Million | +3.42% |
| 2017-12-31 | $335.52 Million | +144.14% |
| 2016-12-31 | $137.43 Million | +35.47% |
| 2015-12-31 | $101.44 Million | +53.20% |
| 2014-12-31 | $66.22 Million | -3.21% |
| 2013-12-31 | $68.41 Million | -6.13% |
| 2012-12-31 | $72.88 Million | +2.69% |
| 2011-12-31 | $70.97 Million | +19.83% |
| 2010-12-31 | $59.22 Million | +68.67% |
| 2009-12-31 | $35.11 Million | +6.27% |
| 2008-12-31 | $33.04 Million | -11.48% |
| 2007-12-31 | $37.33 Million | -45.39% |
| 2006-12-31 | $68.35 Million | +82.55% |
| 2005-12-31 | $37.44 Million | +307.75% |
| 2004-12-31 | $9.18 Million | +61.18% |
| 2003-12-31 | $5.70 Million | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more